Editorial

Drug-Induced Sexual Problems

Authors: James M. Wooten, PharmD

Abstract

Adverse drug reactions have become a major cause of morbidity to all patients. This is no wonder, since the number of medications approved by the United States Food and Drug Administration (FDA) has risen exponentially over the years. With the increasing pressure of pharmaceutical companies to have their product approved by the FDA because of cost constraints and other factors, and with the increasing pressure of the FDA to get new, novel, and potentially beneficial drug treatments to consumers, some new drugs can potentially have an adverse effect profile that is somewhat incomplete and may not be readily known until the drug is on the market for some period of time or until postmarketing surveillance on the product is completed. Rather than focus on all adverse drug effects, this discussion will focus only on one type: drug-induced sexual dysfunction.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1.Bell DS. Peyronie disease in association with carvedilol: a case report. South Med J 2008;101:1157–1158.
 
2.McVary KT. Clinical practice. Erectile dysfunction. N Engl J Med 2007;357:2472–2481.
 
3.Thomas DR. Medications and sexual function. Clin Geriatr Med 2003;19:553–562.
 
4.Tikkanen MJ, Jackson G, Tammela T, et al. Erectile dysfunction as a risk factor for coronary heart disease: implications for prevention. Int J Clin Pract 2007;61:265–268.
 
5.Vandenbroucke JP. In defense of case reports and case series. Ann Intern Med 2001;134:330–334.
 
6.FDA Med Watch. Food and drug administration. Available at: http://www.fda.gov/medwatch/